글로벌 교모세포종 치료 시장 – 2023-2030

Market Overview
The global glioblastoma treatment market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).
Glioblastoma is also known as glioblastoma multiforme (GBM). Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age but tends to occur more often in older adults. Treatments include radiation, chemotherapy and surgery.
Market Dynamics
Governments and non-government bodies undertake various initiatives to raise awareness about glioblastoma multiforme. Strong R&D Initiatives from key players, rising incidence of glioblastoma multiforme and increasing US FDA approval of new drugs are the factors to drive the market in the forecast period.
Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.
Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps raise awareness about glioblastoma multiforme and motivates people to donate money for glioblastoma multiforme research activities. Moreover, organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The campaign's main aim is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Additionally, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month. These factors are driving the growth of the market in the forecast period.
The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.
The direct medical costs of newly diagnosed TMZ-treated GBM in commercially insured patients are substantial, with estimated costs of $268,031. Extensive studies have been conducted to decrease the direct costs associated with care for patients with glioblastoma. Direct costs are those attributable to the disease, including all the associated therapies and costs associated with managing the disease, which may be borne by various parties (including the patient), depending on factors such as insurance status. The majority of direct costs were incurred in the first four months of treatment, with a plateau in costs beyond one year, reflecting the poor survival of this disease. Radiation and surgery contribute most to the direct costs of GBM. Thus, from the above factors, the market is expected to be hampered in the forecast period.
COVID-19 Impact Analysis
Cancer patients, in general, and glioblastoma patients, are at a higher risk of developing complications from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and striking a balance between the risk of infection and the clinical benefit of treatment is ideal. This group of tumors' aggressive behavior justifies the need for a multidisciplinary team to assist in clinical decisions during the current pandemic. COVID-19's role in the tumorigenesis of solid cancer is unknown, and its role in glioma pathophysiology has not been reported. Glial and neuronal cells are known to express ACE2 on their surfaces, making neuronal cells a potential target for COVID-19 infection.
The current high-grade glioma (HGG) treatment guidelines provide an evidence-based care framework to improve progression-free and overall survival (OS). During the pandemic, doctors must strike a balance between the risks of COVID-19 in a vulnerable population and the risk of under-treatment cancer patients. Furthermore, there is a societal need for healthcare workers to be protected and for secondary viral spread to patients to be avoided. Approaching glioblastoma patients during the COVID-19 pandemic is difficult in most neuro-oncology centers. Significant healthcare disparities between Brazilian states make it difficult for physicians to make appropriate treatment decisions. Patients with good performance status and molecular profile should receive the standard treatment protocol, including the safest resection and concurrent chemo-radiotherapy.
Older patients and those with poor performance status should be treated with caution, and a monotherapy regimen may be best suited during the COVID-19 pandemic unless patients with good performance status and no comorbidities benefit from hypofractionated protocols with temozolomide. The current situation adds new challenges to providing the best healthcare possible, and finding new ways to communicate with patients is critical. However, the situation is expected to improve gradually in the forecast period.
Segment Analysis
Chemotherapy segment is expected to hold the largest market share in glioblastoma treatment market
Glioblastoma multiforme (GBM) is adults' most common primary brain tumor. No specific medications exist to treat GBM. However, certain conditions require medical treatment. For seizures, the patient usually is started on levetiracetam (Keppra), phenytoin (Dilantin), or carbamazepine (Tegretol). Levetiracetam is often used because it lacks the effects on the P450 system seen with phenytoin and carbamazepine, which can interfere with antineoplastic therapy. Chemotherapy is a common type of treatment for glioblastoma multiforme. Most patients begin chemotherapy two to four weeks after surgery, concurrently or shortly after radiation therapy. Chemotherapy is sometimes the primary treatment when a tumor cannot be surgically removed. It works by using powerful medications to destroy rapidly dividing cancer cells. These medications can be taken as pills, injected into a vein, or, in some cases, injected into the intrathecal space of the spine.
Chemotherapy for glioblastoma requires a high level of expertise because tumors are frequently made up of multiple types of cells. Some medications may kill some of these cells while allowing others to proliferate unhindered. As a result, medical oncologists must carefully tailor treatment plans for glioblastoma patients. These factors will drive the segment's growth during the forecast period. Efforts to develop new treatments have focused on discovering new drug targets and categorizing patients based on age and molecular cancer markers. Immunotherapy, RIT, or dietary treatments combined with standard radio(chemo)therapy are other promising research avenues currently in translational development. Patients undergoing chemotherapy are given drugs that are designed to kill tumor cells. The current gold standard of treatment for GBM is chemotherapy with temozolomide. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.
Geographical Analysis
North America region holds the largest market share in the global glioblastoma treatment market
North America region accounted for the largest market share in 2021. Owing to significant market players, increasing healthcare awareness, and FDA approvals for novel drugs and the development of advanced treatment methods that counter glioma stem cells' resistive properties are also positively influencing market growth. Additionally, increasing research and development (R & R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. New drug approvals and launches for GBM treatment are expected to drive market growth in the region. For instance, in January 2020, Pfizer launched 'Zirabev' in the U.S. It is a bevacizumab biosimilar to Avastin, approved for treating recurrent glioblastoma multiforme.
Additionally, On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM). Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.
Competitive Landscape
Major key players in the glioblastoma treatment market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.
On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM).
Genentech Inc.:
Overview:
Genentech Inc. is a biotechnology company based in the United States that became a subsidiary of Roche in 2009. The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche. Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.
Product Portfolio:
Avastin (bevacizumab): Avastin (bevacizumab) is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).
The global glioblastoma treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.